The NY Times reports that a federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property.
U.S. Judge Invalidates Human Gene Patent
2 Comments
Recent Posts
New Rights, New Powers, Long Delays: Bill C-36’s Seven-Step Process for Privacy Reform to Take Effect 
The Law Bytes Podcast, Episode 273: Rebroadcast of the Globe and Mail’s The Decibel on Canada’s First Steps Towards a Social Media Ban 
Midnight Madness: The Government Rushes Lawful Access Bill Through the House Without Debate or a Recorded Vote 
One Step Forward, Two Steps Back: Bill C-36 Modernizes Canada’s Privacy Law, Then Delays It to 2030 
Gary Anandasangaree’s Vic Toews Moment Shows the Government Has Lost Its Way on Lawful Access
“Myriad Genetics, the company that holds the patents with the University of Utah Research Foundation, asked the court to dismiss the case, claiming that the work of isolating the DNA from the body transforms it and makes it patentable. ”
So, they claim they aren’t actually patenting the two genes, they are patenting transformed version of the genes? To me this would invalidate the work of the human genome project, as they cataloged not the human genome but some variation thereof… Or am I understanding the claim incorrectly?
They’re claiming that isolated DNA is “transformed”, so the not-found-in-nature requirement of a patent doesn’t apply to the genes.